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Porphyromonas gingivalis infection may contribute to systemic and intracerebral 8 
amyloid-beta: Implications for Alzheimer’s disease onset  9 
 10 





The microbiota of “chronic” periodontitis, particularly Porphyromonas gingivalis, have been 13 
implicated in Alzheimer’s disease (AD) because this bacterium has a range of enzymes 14 
(cathepsin B and gingipains) that are shown to interact with the amyloid precursor protein 15 
(APP) and neuronal tau resulting in the formation of amyloid-beta (Aβ) and neurofibrillary 16 
tangles (NFTs). These two lesions remain pivotal to explaining AD pathogenesis alongside of 17 
clinical symptoms. Deposits of Aβ in the brain can start 10-20 years before the clinical 18 
symptoms of cognitive decline and the diagnosis of AD is established. It is rarely mentioned 19 
that the AD risk doubles if the individual has received a diagnosis of periodontitis for around 20 
10 years. This editorial is a review of recent but salient literature supporting the idea that 21 
periodontal disease can contribute to a systemic Aβ pool that may enter the brain over time. In 22 
addition, intracerebral production of Aβ can be initiated by P. gingivalis, which occurs via 23 
host and bacterially derived cathepsin B acting as β-secretase to process the APP via the 24 
amyloidogenic pathway yielding Aβ3-42. These findings support a systemic and an 25 
intracerebral Aβ contribution from “chronic” periodontitis in subsequent AD development. 26 
 27 





 Generalized (“chronic”) periodontitis, a common inflammatory disease affecting the 30 
supporting tissues of teeth, has been associated with several systemic diseases, e.g. 31 
cardiovascular diseases, diabetes, adverse pregnancy outcomes, rheumatoid arthritis, 32 
respiratory diseases, and Alzheimer’s disease (AD).1-7 Bacteria of the periodontal pocket can 33 
spread through the blood stream, which is the common but not the only way of systemic 34 
bacterial dissemination in periodontitis.8 Dental treatment, tooth brushing, flossing, chewing, 35 
and use of tooth-picks in a patient with periodontitis will release a bacteremia.9 This can occur 36 
several times during the day and has been estimated to last for up to 3 hours.10 Tooth-related 37 
bacteremia contains a wide spectrum of bacteria11 among which the Gram-negative anaerobic 38 
rod Porphyromonas gingivalis seems to have a key role in the adult form of generalized  39 
periodontitis.12,13 40 
 A plethora of studies firmly place P. gingivalis but not its companion species (for 41 
example Tannerella forsythia and Treponema denticola in the red complex13) as a risk factor 42 
for AD. This is because P. gingivalis is adept at modifying the peripheral and intracerebral 43 
immune responses.14-16 Furthermore, this bacterium has a range of enzymes including 44 
cathepsin B17 and gingipains18 that are respectively shown to interact with the amyloid 45 
precursor protein (APP) and neuronal tau resulting in the formation of amyloid-beta (Aβ) and 46 
neurofibrillary tangles (NFTs),19,20 which are the cardinal hallmarks of AD. Prospective, 47 
retrospective population-based and nested control studies have shown that the risk of 48 
developing the sporadic form of AD doubles when periodontal disease persists for about ten 49 
years.21-23 This is evident from the fact that a large section of individuals who go on to 50 
developing clinical AD also suffers from periodontitis.  51 
Brain inflammation, characterized by increased activation of microglia and astrocytes, 52 
increases during aging and is a key feature of AD.24 This has been explained in terms of the 53 
hallmark lesions of AD, which are Aβ40/42 extracellular deposits in the form of plaques and 54 
hyperphosphorylated tau protein associating with intraneuronal lesions called NFTs. 55 
Accumulation of Aβ plaques results from the proteolytic cleavage of the APP by β- and γ-56 
secretase enzymes.25,26 These secretases are different in AD driven by bacterial infections 57 
compared to the classically described site-specific secretases in the mutated APP of AD.27, 28 58 
Similarly, toxic proteases from P. gingivalis called gingipains have been identified in the 59 




Aβ is classically believed to be produced by neurons within the AD brain irrespective 61 
of the trigger that causes its release. However, this view is changing, as some researchers 62 
believe the peripheral/systemic Aβ pool is also a contribution from platelets, skeletal muscle 63 
cells, skin fibroblasts, and monocyte/macrophages29-31 and this has implications for AD 64 
pathogenesis over time. Production of inflammagens such as gingipains and 65 
lipopolysaccharide (LPS) secreted by P. gingivalis also occurs in the periodontal pocket 66 
where inflammatory macrophages are reported to bear Aβ.32 Gil-Montoya et al.33 have 67 
reported increased plasma Aβ1-42 levels in individuals who have severe periodontal disease. 68 
Thus Leira et al.34 found when experimental periodontitis was induced in Sprague-Dawley 69 
rats, a strong positive correlation between alveolar bone loss and Aβ1-40 serum levels at 7 days 70 
(r = 0.695, P = 0.012) and with serum Aβ1-42 concentrations at 21 days (r = 0.968, P = 0.002).  71 
Taken together, Aβ also being generated peripherally in platelets, skin fibroblasts and skeletal 72 
muscles 29, 30  may enter the circulating blood.31 The present editorial aims to discuss whether 73 
P. gingivalis can contribute to systemic and intracerebral pools of Aβ. 74 
 75 
P. gingivalis induces systemic Aβ production in infected mice 76 
Nie et al.32 recently reported that chronic, systemic P. gingivalis infection increased the 77 
inflammatory responses and proteins associated with Aβ-production in the liver of mice. The 78 
liver was chosen for the peripheral Aβ source in macrophages because of the general 79 
abundance of these cells.32 Nie et al.32 observed that P. gingivalis infection in mouse liver 80 
macrophages, caused a rapid production of interleukin 1-beta (IL-1β) and thereafter an 81 
intracellular accumulation of Aβ through activation of Toll like receptor 2 /nuclear factor 82 
kappaB (TLR2/NF-κB) signaling. NF-κB-dependent cathepsin B appeared crucial for 83 
cleaving pro-IL-1β and processing APP to induce the accumulation of pathogenic Aβ3-42, 84 
which was significantly increased in liver macrophages of the P. gingivalis-infected mice. 85 
This original study demonstrated peripheral pools of Aβ due to periodontitis in macrophages 86 
within the periodontal tissue and in mice hepatic macrophages following P. gingivalis 87 
infection. In a follow-up study, Zeng et al.17 induced systemic P. gingivalis infection in mice 88 
by intraperitoneal injections containing (1 x 108 CFU/mouse every three days) for three 89 
weeks. This significantly increased the expression of the advanced glycation end products 90 
(RAGE) receptor in the cluster of differentiation 31 (CD31)-positive endothelial cells. This 91 
implied that P. gingivalis systemic infection up-regulated RAGE expression in cerebral 92 
endothelial cells and facilitated Aβ entry into the mouse brain. Cathepsin B was suggested to 93 




ĸB/RAGE expression and in the processing of APP. This study further supported the Nie et 95 
al.32 concept for the potential in systemic spread of peripheral Aβ to the brain from P. 96 
gingivalis infection. In a proof of concept study, Bu et al.31 had demonstrated the plausibility 97 
of peripheral Aβ entry to the brain being facilitated by the RAGE receptor within cerebral 98 
endothelial cells.17 An alternative mode of peripheral Aβ entry into the brain is via 99 
macrophages of the lymphatic system.35 100 
Another focus of Nie and colleagues32 was Aβ1-42, which is classically considered as 101 
the toxic form of Aβ. They observed that Aβ3-42 (Fig. 1) not only occurred earlier but was also 102 
two-fold higher than Aβ1-42 in the AD brain.
32 In AD, Cathepsin B stimulated intracellular 103 
production of Aβ in the brain, including the Aβ3-42. Interestingly, Aβ3-42 following P. 104 
gingivalis-infection in mice generated IL-1β, which is a proinflammatory cytokine.
32 IL-1β, 105 
participated in increasing the in vivo levels of Aβ3-42 in the hepatic macrophages of P. 106 
gingivalis-infected mice and in vitro P. gingivalis-infected macrophages. Furthermore, Aβ3-42 107 
was induced by P. gingivalis infection, which had caused significant death of macrophages 108 
and reduced their phagocytic capacity compared to that of Aβ1-42, suggesting Aβ3-42 is very 109 
toxic. Aβ3-42 was also detected exclusively in the AD brain, and this corroborates with the 110 
significantly more toxic form than Aβ1-42.
32 This study agreed with that of Leira et al.34 who 111 
reported that LPS from P. gingivalis increased Aβ protofibrils in the serum of rats. After 112 
experimental periodontitis had been induced in male Sprague-Dawley rats it caused an acute 113 
elevation of Aβ1-40 in serum that lasted during the whole experiment. Aβ1-42 peptide levels 114 
however, peaked at the end of the study.  115 
 116 
P. gingivalis also generates Aβ in the periodontium and within the brain 117 
Systemically produced Aβ probably occurs in addition to locally generated Aβ in the 118 
periodontium and in the brain induced by P. gingivalis. As mentioned, Leira et al.34 found a 119 
strong positive correlation between alveolar bone loss and Aβ1-40 serum levels at 7 days 120 
(r = 0.695, P = 0.012) and with serum Aβ1-42 concentrations at 21 days (r = 0.968, P = 0.002). 121 
Intracerebral production of Aβ generated by P. gingivalis has been seen in the brain of 122 
experimental wild type animals and with AD transgenes.19, 30-32 Ilievski et al.19 found that 123 
chronic oral application of P. gingivalis to wild type mice resulted in deposition of 124 
extracellular Aβ1-42 together with neurodegeneration and intracerebral inflammation, as 125 




LPS from P. gingivalis for five consecutive weeks caused learning and memory deficits 127 
together with intracellular accumulation of Aβ in neurons of middle-aged wild-type mice. 128 
Taken together, these reports suggest that P. gingivalis can induce both a local periodontal 129 
and a systemic Aβ production, thereby contributing to a pool of Aβ that can enter the brain 130 
facilitated by the endothelial RAGE receptor. 131 
  132 
P. gingivalis interferes with components of the peripheral immune system aimed to 133 
defend the brain  134 
Unexpectedly, recent research has shown that even components of the peripheral immune 135 
system, such as macrophages can participate in defending the brain from insults occurring 136 
outside the brain.38 However, P. gingivalis has the ability to abolish the anaphylatoxin 137 
complement component 5a (C5a) in macrophages thereby undermining TLR2/4 immunity and 138 
degrade some of the complement receptor 1 (CR1) molecules that help clear amyloid via the 139 
spleen.39 Whether this affects other macrophages in a similar way is not known. Further 140 
immune evasion strategies of P. gingivalis in relation to AD are discussed elsewhere.40  141 
 142 
Concluding remarks 143 
We have communicated that monocytes/macrophages from the periodontium and the liver 144 
may provide an additional circulating pool of unique Aβ3-42 fragments in patients with 145 
periodontitis. Entry of P. gingivalis and/or its gingipains and LPS into the brain due to a 146 
defective blood-brain barrier can lead to intracerebral deposition of Aβ plaques. These 147 
findings support the notion that the adult form of generalized periodontitis via P. gingivalis, 148 
contributes to both an oral and hepatic cellular source of cells that add to the systemic pool of 149 
Aβ. This peptide can also be a contribution of other cell sources of peripheral organs like skin 150 
smooth cells and platelets which have the potential to transport Aβ to the brain and over time  151 
may play a role in AD pathogenesis. Deposits of Aβ in the brain can start 10-20 years before 152 
cognitive decline and the diagnosis of AD. This agrees with the timeline of at least 10 years 153 
required for periodontitis to initiate AD and emphasizes the need for meticulous dental 154 
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Figure legend 298 
Fig. 1 summarizes the Nie et al.32 vision as interpreted by Olsen and Singhrao for the 299 
contribution to AD of peripheral pools of Aβ, specifically Aβ3-42. It is generated by P. 300 
gingivalis (Pg) oral infection that eventually reaches the liver and the brain. The proposed 301 
signaling pathway (TLR2,4/NF-ĸB) is also indicated where it is likely to act liberating 302 
interleukin-1β (IL-1β) cytokine that facilitates the amyloid precursor protein cleavage of Aβ 303 
via secretase enzymes, one of which is cathepsin B.  The low-density lipoprotein 304 
receptor-related protein 1 (LRP1) is the receptor for Aβ transport from the brain to the 305 
peripheral blood. The Aβ from the systemic circulation can enter the brain using the advanced 306 
glycation end products (RAGE) receptor. Nie et al.32 have shown Aβ within the gingival 307 
tissues of periodontitis patients and in the liver of middle-aged mice after chronic systemic P. 308 
gingivalis infection, thereby contributing to the peripheral pools of Aβ. Some researchers 309 
believe the peripheral Aβ also comes from platelets, skeletal muscle cells, skin fibroblasts, 310 
and monocyte/macrophages. The implications of the peripheral Aβ is that it can also enter the 311 
brain and contribute to AD pathology as shown by Bu et al.31 312 
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